ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,187.67
0.00%
Dow Jones
39,056.39
0.44%
US Dollar vs MXN
16.94665
0.16%
Brent Oil
83.65
0.11%
Bitcoin
61,547.90
0.59%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE
  6. Johnson & Johnson (0R34)

  7. Johnson & Johnson (0R34) Noticias

0R34

Johnson & Johnson (0R34)

Johnson & Johnson
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:0R34
FechaHoraFuenteTítuloSímboloCompañía
01/05/202408:17Alliance NewsAlliance NewsTOP NEWS: J&J proposes USD6.48 billion settlement of cancer lawsuitsLSE:0R34Johnson & Johnson
16/04/202405:54Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson upgrades guidance on swing to earningsLSE:0R34Johnson & Johnson
05/04/202406:02Alliance NewsAlliance NewsTOP NEWS: J&J swoops for Shockwave Medical in USD13.1 billion dealLSE:0R34Johnson & Johnson
25/03/202413:28Alliance NewsAlliance NewsIN BRIEF: J&J submits US premarket approval application for VaripulseLSE:0R34Johnson & Johnson
18/03/202406:10Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson receives FDA recommendation for CarvyktiLSE:0R34Johnson & Johnson
23/02/202412:32Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson gets EMA nod for Carvykti in myelomaLSE:0R34Johnson & Johnson
02/02/202400:22Alliance NewsAlliance NewsTOP NEWS: US sends drugmakers initial offers in Medicare price talksLSE:0R34Johnson & Johnson
23/01/202405:41Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson eyes future growth; 2023 sales riseLSE:0R34Johnson & Johnson
19/01/202415:34Alliance NewsAlliance NewsIN BRIEF: J&J gets US FDA approval for cancer treatment BalversaLSE:0R34Johnson & Johnson
05/12/202307:24Alliance NewsAlliance NewsTOP NEWS: J&J expects strong long-term growth in three key driversLSE:0R34Johnson & Johnson
23/10/202306:03Alliance NewsAlliance NewsJ&J report slew of positive trial results focused on various cancersLSE:0R34Johnson & Johnson
17/10/202305:46Alliance NewsAlliance NewsTOP NEWS: J&J raises full-year sales outlook after "solid" quarterLSE:0R34Johnson & Johnson
06/10/202310:52Alliance NewsAlliance NewsIN BRIEF: J&J applies for indication extension to EMA for RybrevantLSE:0R34Johnson & Johnson
03/10/202311:00Alliance NewsAlliance NewsDrugmakers agree to US government price talks amid pushbackLSE:0R34Johnson & Johnson
07/09/202300:50Alliance NewsAlliance NewsJ&J's Janssen ends Phase 3 MACiTEPH study evaluating macitentanLSE:0R34Johnson & Johnson
30/08/202311:07Alliance NewsAlliance NewsTOP NEWS: J&J forecasts strong growth in earnings after Kenvue splitLSE:0R34Johnson & Johnson
10/08/202315:34Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson's blood cancer therapy approved by FDALSE:0R34Johnson & Johnson
20/07/202306:30Alliance NewsAlliance NewsTOP NEWS: J&J ups full-year guidance after "robust" second quarterLSE:0R34Johnson & Johnson
30/05/202310:48Alliance NewsAlliance NewsJ&J seeks FDA approval for pulmonary arterial hypertension treatmentLSE:0R34Johnson & Johnson
09/05/202314:23Alliance NewsAlliance NewsJ&J says Tremfya data shows positive results for ulcerative colitisLSE:0R34Johnson & Johnson
04/05/202306:41Alliance NewsAlliance NewsIN BRIEF: J&J prices subsidiary Kenvue's NYSE initial public offeringLSE:0R34Johnson & Johnson
01/05/202301:51Alliance NewsAlliance NewsJohnson & Johnson reports first results from TAR-200 studyLSE:0R34Johnson & Johnson
18/04/202306:06Alliance NewsAlliance NewsTOP NEWS: J&J swings to first quarter loss due to litigation costsLSE:0R34Johnson & Johnson
05/04/202300:01Alliance NewsAlliance NewsJ&J proposes USD8.9 billion settlement of talc cancer claimsLSE:0R34Johnson & Johnson
04/04/202315:57Alliance NewsAlliance NewsIN BRIEF: J&J subsidiary re-files for bankruptcy amid talc claimsLSE:0R34Johnson & Johnson
17/03/202313:04Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson notes positive data for psoriasis drugLSE:0R34Johnson & Johnson
24/01/202306:33Alliance NewsAlliance NewsTOP NEWS: J&J fourth-quarter revenue falls on fewer Covid jab salesLSE:0R34Johnson & Johnson
05/01/202303:06Alliance NewsAlliance NewsJohnson & Johnson's consumer health unit files to go publicLSE:0R34Johnson & Johnson
09/12/202210:51Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson submits licence application to FDALSE:0R34Johnson & Johnson
01/12/202205:37Alliance NewsAlliance NewsJohnson & Johnson appoints Chief Executive Joaquin Duato as new chairLSE:0R34Johnson & Johnson
 Showing the most relevant articles for your search:LSE:0R34

Su Consulta Reciente

NASDAQ
NVDA
NVIDIA
AMEX
XLE
Energy Select Sector SPDR
CCOM
SILVER
SILVER
NASDAQ
GOOGL
Alphabet
PM
XAUUSD
Gold vs US Dollar
NYSE
KO
Coca Cola
NYSE
AXP
American Express
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
JPM
JP Morgan Chase
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
CVX
Chevron
NASDAQ
AAPL
Apple
SPI
SP500
S&P 500
NYSE
DIS
Walt Disney
AMEX
SPY
SPDR S&P 500
NYSE
MCD
McDonalds
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados